Skip to Content

Cabometyx Approval History

  • FDA approved: Yes (First approved April 25th, 2016)
  • Brand name: Cabometyx
  • Generic name: cabozantinib
  • Dosage form: Tablets
  • Company: Exelixis, Inc.
  • Treatment for: Renal Cell Carcinoma

Cabometyx (cabozantinib) is a tyrosine kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma (RCC).

Development History and FDA Approval Process for Cabometyx

DateArticle
Dec 19, 2017Approval Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
Apr 26, 2016Approval Exelixis Announces FDA Approval of Cabometyx (cabozantinib) for Patients with Advanced Renal Cell Carcinoma
Feb  1, 2016Exelixis Announces Positive Overall Survival Results from METEOR, the Phase 3 Pivotal Trial of Cabozantinib in Advanced Renal Cell Carcinoma
Jan 28, 2016Exelixis Announces U.S. FDA Deems NDA Sufficiently Complete and Grants Priority Review for Cabozantinib as a Treatment for Advanced Renal Cell Carcinoma

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide